Barzolvolimab Improves Angioedema in CSU
Barzolvolimab ”profoundly” improves angioedema in patients with chronic spontaneous urticaria (CSU), according to new Phase 2 data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 in Valencia, Spain. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, […]